Horm Metab Res 2019; 51(08): 487-494
DOI: 10.1055/a-0958-2441
Review
© Georg Thieme Verlag KG Stuttgart · New York

Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes

Peili Wu*
1  Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Weiheng Wen*
1  Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Jitong Li*
1  Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Jie Xu
1  Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Min Zhao
1  Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Hong Chen
1  Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
,
Jia Sun
1  Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, P. R. China
› Author Affiliations
Further Information

Publication History

received 25 September 2018

accepted 12 June 2019

Publication Date:
13 August 2019 (online)

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibitors are a new kind of hypoglycemic drugs that improve glucose homeostasis by inhibiting renal glucose reabsorption. Recent studies have shown that SGLT2 inhibitors can also mediate body metabolism through regulation of adipokines level, but the effects of SGLT2 inhibitors on the concentration of adipokines (leptin and adiponectin) remains controversial. This meta-analysis was set out to evaluate the changes in circulating leptin and adiponectin levels in patients with type 2 diabetes mellitus (T2DM) receiving SGLT2 inhibitors therapy. Ten randomized controlled trials (RCTs), that evaluated the effects of SGLT2 inhibitors on blood leptin and adiponectin levels in patients with type 2 diabetes, were identified by performing a systematic search of Pubmed, Embase, Cochrane, and Web of science databases through July 2018. Data were calculated using a random-effects model and presented as standardized mean difference (SMD) and 95% confidence interval (CI). Compared with placebo, treatment with SGLT2 inhibitors contributed to a decreased circulating leptin levels (SMD −0.29, 95% CI −0.56, −0.03) and an increased circulating adiponectin levels (SMD 0.30, 95% CI 0.22, 0.38). SGLT2 inhibitor treatment was associated with decreased circulating leptin levels and increased circulating adiponectin levels, which might contribute to the beneficial effects of SGLT2 inhibitors on metabolic homeostasis.

* Contributed equally to this work.


Supplementary Material